Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation

Gastroenterology

Volumn 141, Issue 2, 2011, Pages 430-434

  Allen, Joshua E ^a,b   El Deiry, Wafik S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CISPLATIN; ETOPOSIDE; OXALIPLATIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; COLON CANCER; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

EID: 80051525732     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.06.026     Document Type: Editorial

References (38)

1. C. Falschlehner, U. Schaefer, and H. Walczak Following TRAIL's path in the immune system Immunology 127 2009 145 154
2. J. Abdulghani, and W.S. El-Deiry TRAIL receptor signaling and therapeutics Expert Opin Ther Targets 14 2010 1091 1108
3. M.S. Ricci, S.H. Kim, and K. Ogi Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death Cancer Cell 12 2007 66 80 (Pubitemid 47001783)
4. Z. El Fajoui, F. Toscano, and G. Jacquemin Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL Gastroenterology 141 2011 663 673
5. J.F. Lovell, L.P. Billen, and S. Bindner Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax Cell 135 2008 1074 1084
6. K.G. Wolter, Y.T. Hsu, and C.L. Smith Movement of Bax from the cytosol to mitochondria during apoptosis J Cell Biol 139 1997 1281 1292 (Pubitemid 27523214)
7. R. Eskes, S. Desagher, and B. Antonsson Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane Mol Cell Biol 20 2000 929 935 (Pubitemid 30044230)
8. S. Hinz, A. Trauzold, and L. Boenicke Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis Oncogene 19 2000 5477 5486 (Pubitemid 32000915)
9. T.F. Burns, and W.S. El-Deiry Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach J Biol Chem 276 2001 37879 37886
10. S. Fulda, E. Meyer, and K.M. Debatin Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression Oncogene 21 2002 2283 2294 (Pubitemid 34407288)
11. H. Walczak, A. Bouchon, and H. Stahl Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells Cancer Res 60 2000 3051 3057 (Pubitemid 30395834)
12. A. Ballestrero, A. Nencioni, and D. Boy Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing Jurkat cells Clin Cancer Res 10 2004 1463 1470 (Pubitemid 38365242)
13. F. Toscano, Z.E. Fajoui, and F. Gay p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells Oncogene 27 2008 4161 4171 (Pubitemid 351969905)
14. R.D. Meng, E.R. McDonald, and M.S. Sheikh The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis Mol Ther 1 2000 130 144
15. S. Haldar, N. Jena, and C.M. Croce Inactivation of Bcl-2 by phosphorylation Proc Natl Acad Sci U S A 92 1995 4507 4511
16. S. Haldar, J. Chintapalli, and C.M. Croce Taxol induces bcl-2 phosphorylation and death of prostate cancer cells Cancer Res 56 1996 1253 1255 (Pubitemid 26080965)
17. T. Ito, X. Deng, and B. Carr Bcl-2 phosphorylation required for anti-apoptosis function J Biol Chem 272 1997 11671 11673 (Pubitemid 27202724)
18. K. Maundrell, B. Antonsson, and E. Magnenat Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1 J Biol Chem 272 1997 25238 25242 (Pubitemid 27415712)
19. K. Yamamoto, H. Ichijo, and S.J. Korsmeyer BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M Mol Cell Biol 19 1999 8469 8478 (Pubitemid 30414041)
20. J. Park, I. Kim, and Y.J. Oh Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2 J Biol Chem 272 1997 16725 16728 (Pubitemid 27289764)
21. K.-J. Park, S.H. Lee, and C.H. Lee Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death Biochem Biophys Res Commun 382 2009 726 729
22. R.J. Davis Signal transduction by the JNK group of MAP kinases Cell 103 2000 239 252
23. C. Tournier, P. Hess, and D.D. Yang Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway Science 288 2000 870 874 (Pubitemid 30257738)
24. M. Fan, M. Goodwin, and T. Vu Vinblastine-induced Phosphorylation of Bcl-2 and Bcl-XL Is Mediated by JNK and Occurs in Parallel with Inactivation of the Raf-1/MEK/ERK Cascade J Biol Chem 275 2000 29980 29985
25. S. Inoshita, K. Takeda, and T. Hatai Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress J Biol Chem 277 2002 43730 43734 (Pubitemid 36157790)
26. A. Nehme, R. Baskaran, and S. Nebel Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells Br J Cancer 79 1999 1104 1110 (Pubitemid 29087882)
27. X. Wang, M. Li, and J. Wang The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells Biochem Pharmacol 71 2006 1540 1550
28. J.M. Woynarowski, S. Faivre, and M.C. Herzig Oxaliplatin-induced damage of cellular DNA Mol Pharmacol 58 2000 920 927
29. J. Liu, and A. Lin Role of JNK activation in apoptosis: a double-edged sword Cell Res 15 2005 36 42 (Pubitemid 41653963)
30. M.A. Bogoyevitch, and B. Kobe Uses for JNK: the many and varied substrates of the c-Jun N-Terminal kinases Microbiol Mol Biol Rev 70 2006 1061 1095 (Pubitemid 44958264)
31. C. Yu, Y. Minemoto, and J. Zhang JNK Suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD Mol Cell 13 2004 329 340 (Pubitemid 38229806)
32. H.W. Lee, S.-S. Lee, and S.J. Lee Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation Cancer Res 63 2003 1093 1100 (Pubitemid 36278443)
33. Y. Lin, A. Devin, and A. Cook The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of Ikappa B kinase and c-Jun N-terminal kinase Mol Cell Biol 20 2000 6638 6645
34. F. Muhlenbeck, E. Haas, and R. Schwenzer TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways J Biol Chem 273 1998 33091 33098 (Pubitemid 28557706)
35. I. Herr, D. Wilhelm, and E. Meyer JNK/SAPK activity contributes to TRAIL-induced apoptosis Cell Death Differ 6 1999 130 135 (Pubitemid 29082301)
36. N. Corazza, S. Jakob, and C. Schaer TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality J Clin Invest 116 2006 2493 2499 (Pubitemid 44330148)
37. N. Ozoren, K. Kim, and T.F. Burn The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand Cancer Res 60 2000 6259 6265
38. S.-H. Kim, K. Kim, and J.G. Kwagh Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells J Biol Chem 279 2004 40044 40052 (Pubitemid 39258279)